PTM-001
/ Phoenicis Therap, AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 26, 2022
Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa
(clinicaltrials.gov)
- P2 | N=50 | Recruiting | Sponsor: Phoenicis Therapeutics | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2022 ➔ Jun 2024 | Trial primary completion date: Sep 2022 ➔ Dec 2023
Enrollment open • Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immune Modulation • Inflammation • IL17A • IL5 • IL6
May 16, 2022
Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: Phoenicis Therapeutics | Initiation date: Sep 2021 ➔ Sep 2022
Trial initiation date • Dermatology • Hidradenitis Suppurativa • Immune Modulation • Inflammation • IL17A • IL1B • IL5 • IL6
August 25, 2021
Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa
(clinicaltrials.gov)
- P2; N=50; Not yet recruiting; Sponsor: Phoenicis Therapeutics
Clinical • New P2 trial • Dermatology • Hidradenitis Suppurativa • Immune Modulation • Inflammation • IL17A • IL1B • IL5 • IL6
1 to 3
Of
3
Go to page
1